Bilateral Cataract after Taking Oxcarbazepine

被引:0
作者
Kim, Hyo Jeong [1 ]
Jung, Na Yeon [1 ]
Yang, Chan Min [1 ]
Chung, Tae-Young [1 ]
Lim, Dong Hui [1 ,2 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea
[2] Catholic Univ Korea, Grad Sch, Dept Prevent Med, Seoul, South Korea
来源
JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY | 2019年 / 60卷 / 05期
基金
新加坡国家研究基金会;
关键词
Anti epileptic drugs; Oxcarbazepine; Subcapsular cataract; CONTROLLED CLINICAL-TRIAL; PHARMACOKINETICS; PHENYTOIN; ADULTS;
D O I
10.3341/jkos.2019.60.5.486
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To report a case of bilateral posterior subcapsular cataract after taking oxcarbazepine (Trileptal((R)), Novartis, Basel, Swiss). Case summary: A 19-year-old female visited our clinic with decreased vision in both eyes. Her best-corrected visual acuity was 0.3 in the right eye and 0.5 in the left eye, and slit-lamp examination revealed a bilateral cortical opacity and subcapsular cataract. She had been taking oxcarbazepine for epilepsy for 10 years, which was discontinued 3 years ago. Her mother had undergone cataract surgeries when she was approximately 46 years of age. No other risk factors for cataract were present. Conclusions: In the present case, bilateral cortical opacity and subcapsular cataract were assumed to be associated with the use of oxcarbazepine. We suggest that oxcarbazepine could induce a cataract and recommend a regular follow-up by a qualified ophthalmologist.
引用
收藏
页码:486 / 490
页数:5
相关论文
共 15 条
[1]  
Banerjee, 2016, BIOCH ANAL BIOCH, Vs3, P255, DOI DOI 10.4172/2161-1009.1000255
[2]  
Berman ER, 1991, BIOCH EYE
[3]   A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy [J].
Bill, PA ;
Vigonius, U ;
Pohlmann, H ;
Guerreiro, CAM ;
Kochen, S ;
Saffer, D ;
Moore, A .
EPILEPSY RESEARCH, 1997, 27 (03) :195-204
[4]  
Brown M, 2008, WOODHEAD PUBL FOOD S, P341, DOI 10.1533/9781845694883.2.341
[5]   A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy [J].
Christe, W ;
Kramer, G ;
Vigonius, U ;
Pohlmann, H ;
Steinhoff, BJ ;
Brodie, MJ ;
Moore, A .
EPILEPSY RESEARCH, 1997, 26 (03) :451-460
[6]   Overview of the clinical pharmacokinetics of oxcarbazepine [J].
Flesch, G .
CLINICAL DRUG INVESTIGATION, 2004, 24 (04) :185-203
[7]  
FRIIS ML, 1993, ACTA NEUROL SCAND, V87, P224
[8]   A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy [J].
Guerreiro, MM ;
Vigonius, U ;
Pohlmann, H ;
deManreza, MLG ;
Fejerman, N ;
Antoniuk, SA ;
Moore, A .
EPILEPSY RESEARCH, 1997, 27 (03) :205-213
[9]   Clinical pharmacokinetics of oxcarbazepine [J].
May, TW ;
Korn-Merker, E ;
Rambeck, B .
CLINICAL PHARMACOKINETICS, 2003, 42 (12) :1023-1042
[10]   OXCARBAZEPINE - MECHANISMS OF ACTION [J].
MCLEAN, MJ ;
SCHMUTZ, M ;
WAMIL, AW ;
OLPE, HR ;
PORTET, C ;
FELDMANN, KF .
EPILEPSIA, 1994, 35 :S5-S9